If you forget cancer and disregard GVHD, Nash, monotherapy and just focus on combo which we are submitting the BLA for in September (possibly) - There are 230,000 class two and three resistant HIV patients if we only got 10% that is 23,000 patients times $35,000 a patient gives you $805 million revenue at 10 times revenue that puts the value of the company at well over $10 a share.